ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer
2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy.
2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications
2010 Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
Capitolo 4 - Terapia Medica
2011 G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
2004 Arpino, Grazia; Valerie J., Bardou; Gary M., Clark; Richard M., Elledge
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
2005 Arpino, Grazia; H. L., Weiss; G. M., Clark; S. G., Hilsenbeck; C. K., Osborne
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
2004 Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
2002 Carlomagno, Chiara; Lauria, Rossella; DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, Erminia; Ferrara, Claudia; Milano, Andrea; Vernaglia, LOMBARDI ALESSANDRA; Costanzo, Raffaele; G., Catalano; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
2007 Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.
2002 Arpino, Grazia; Gary M., Clark; Syed, Mohsin; Valerie J., Bardou; Richard M., Elledge
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge | |
| The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino | |
| Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Imaging tests in staging and surveillance of early breast cancer in Italy. changes in routine clinical practice and costs implications | 1.5 Abstract in rivista | 2010 | Cammarota, Simona; Menditto, Enrica; Citarella, Anna; Putignano, D.; Riegler, S.; Arpino, Grazia | |
| Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
| Capitolo 4 - Terapia Medica | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco | |
| Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. | 1.1 Articolo in rivista | 2004 | Arpino, Grazia; Valerie J., Bardou; Gary M., Clark; Richard M., Elledge | |
| Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; H. L., Weiss; G. M., Clark; S. G., Hilsenbeck; C. K., Osborne | |
| HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. | 1.1 Articolo in rivista | 2004 | Arpino, Grazia; Stephanie J., Green; D., Craig Allred; Dannika, Lew; Silvana, Martino; C., Kent Osborne; Richard M., Elledge | |
| Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. | 1.1 Articolo in rivista | 2002 | Carlomagno, Chiara; Lauria, Rossella; DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, Erminia; Ferrara, Claudia; Milano, Andrea; Vernaglia, LOMBARDI ALESSANDRA; Costanzo, Raffaele; G., Catalano; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. | 1.1 Articolo in rivista | 2007 | Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm | |
| Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. | 1.1 Articolo in rivista | 2002 | Arpino, Grazia; Gary M., Clark; Syed, Mohsin; Valerie J., Bardou; Richard M., Elledge |